title: Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group.
abstract: OBJECTIVE
  to compare standard and alternating administration of chemotherapy combinations in small cell lung cancer (SCLC) patients.
  
  
  METHODS
  in a multicenter clinical trial, 394 previously untreated SCLC patients were randomised to receive, every 4 weeks, eight courses of either a standard regimen with CCNU, cyclophosphamide, adriamycin (CCA) and VP16 or an alternating regimen (CCA regimen alternating with cisplatin-vindesine-VP16).
  
  
  RESULTS
  overall response rate was higher in the standard group (78%) than in the alternating group (64%) (P = 0.0001). Complete response rate was also higher in the standard group (32%) than in the alternating group (18%) (P = 0.004). The median survival in the overall SCLC population was 306 days in the standard group and 272 days in the alternating group (P = 0.08). In limited SCLC patients, median survival was higher in the standard group (421 days) than in the alternating group (328 days) (P = 0.01). Grade III/IV haematological toxicity was lower in patients in the alternating group (25 versus 47%) (P < 0.001).
  
  
  CONCLUSIONS
  the standard regimen was better than the alternating regimen for patients with limited forms of SCLC. The alternating regimen, associated with better haematological safety and ensuring a fairly similar survival, may be considered in patients with extensive SCLC. Pleiomorphic resistance mechanisms to chemotherapy make it difficult to define a non-cross-resistant chemotherapy regimen.
authors.affiliation: Service de pneumologie, Hôpital Saint-Antoine, Paris, France. thierry.urban@sat.ap-hop-paris.fr
authors.forename: T
authors.initials: T
authors.lastname: Urban
authors.forename: T
authors.initials: T
authors.lastname: Baleyte
authors.forename: C L
authors.initials: CL
authors.lastname: Chastang
authors.forename: L
authors.initials: L
authors.lastname: Jeannin
authors.forename: P
authors.initials: P
authors.lastname: Delaval
authors.forename: M
authors.initials: M
authors.lastname: Zaegel
authors.forename: M
authors.initials: M
authors.lastname: Mornet
authors.forename: D
authors.initials: D
authors.lastname: Coetmeur
authors.forename: B
authors.initials: B
authors.lastname: Lebeau
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D005047:Etoposide; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D006493:Heparin